NICE confirms earlier draft recommendation for Lilly's GLP1-agonist
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has re-affirmed its initial draft recommendation for the use of Lilly/Amylin's GLP1-agonist, Bydureon (exenatide extended-release for injectable suspension), in patients with type 2 diabetes.